Korro Bio is a biotechnology company that is focused on the discovery and development of gene therapies for the treatment of genetic diseases. The company's proprietary gene editing platform enables the precise modification of disease-causing genes in vivo. Korro Bio's lead program is focused on the development of a gene therapy for the treatment of sickle cell disease, a genetic disorder that affects the production of hemoglobin. The company is headquartered in Cambridge, Massachusetts.